arrow
H

Haley B. Naik

university of california
H指数:28
被引数:3,761

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Bimekizumab在治疗中度至重度化脓性汗腺炎的患者中,显示出良好的安全性和高水平的疗效,治疗时间长达2年:来自两项III期随机对照试验及其开放标签扩展研究的合并结果

2025-11-150
PRE
Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens
2025-01-010
PRE
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
2024-12-011
PRE
The Global Hidradenitis Suppurativa Atlas Methodology: Combining Global Proportions in a Pooled Analysis
2024-02-146
OA
Global consensus process to establish a core dataset for hidradenitis suppurativa registries

建立化脓性汗腺炎登记处核心数据集的全球共识进程

2023-11-171
OA
Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice A HiSTORIC Consensus Statement

临床实践中评估化脓性汗腺炎治疗反应的结果指标历史性共识声明

2023-11-012
OA